Working… Menu
Trial record 14 of 32 for:    Hydrogen Sulfide

A Trial of Vitamin B12 in Septic Shock (B12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03783091
Recruitment Status : Recruiting
First Posted : December 20, 2018
Last Update Posted : August 28, 2019
Information provided by (Responsible Party):
Jayshil J. Patel, MD, Medical College of Wisconsin

Brief Summary:
This study will randomize 30 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to reduce vasopressor dose at 3 hours.

Condition or disease Intervention/treatment Phase
Septic Shock Drug: Hydroxocobalamin Drug: Placebo Phase 2

Detailed Description:
Following informed consent from patient's legally authorized representative, patients will be randomized to hydroxocobalamin or saline. Patients will have blood samples drawn up to 3 hours pre-dose and 3 hours post-dose to measure for hydrogen sulfide levels. Patients will also be followed for 3 hours after study drug infusion to monitor and record vasopressor dependence in norepinephrine-equivalent dose. Patients will then be followed through their medical record for 28 days to determine persistent organ dysfunction syndrome (PODS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: Vitamin B12a is bright red and excreted in the urine. Due to this, patient allocation cannot be masked for patients or individuals who may care for them.
Primary Purpose: Treatment
Official Title: A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock
Actual Study Start Date : August 5, 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: B Vitamins Shock

Arm Intervention/treatment
Experimental: Hydroxocobalamin
Single IV infusion administered over a 10-15 minute period
Drug: Hydroxocobalamin
Single IV administration of Vitamin B12
Other Name: Cyanokit

Placebo Comparator: Saline Placebo
Single IV saline administered over a 10-15 minute period.
Drug: Placebo
Single IV administration of saline
Other Name: 200-250 mL of intravenous saline or dextrose

Primary Outcome Measures :
  1. Vasopressor Support [ Time Frame: 28 days ]
    Vasopressor support as documented by administered vasopressor amounts

Secondary Outcome Measures :
  1. Hydrogen Sulfide Concentration [ Time Frame: 3 hours ]
    Difference between pre- and post-dose hydrogen sulfide levels

  2. Persistent Organ Dysfunction Syndrome (PODS) [ Time Frame: 28 days ]
    Prevalence of Persistent organ dysfunction syndrome (PODS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult patients at least 18 years of age
  • Admitted to the Medical Intensive Care Unit (MICU) service at Froedtert Hospital

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03783091

Layout table for location contacts
Contact: Jayshil J Patel, MD 414-955-7040
Contact: Jeanette Graf, BS 414-955-6987

Layout table for location information
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Jayshil J Patel, MD    414-955-7040      
Contact: Jennifer Peterson, PhD    414-955-7085   
Sponsors and Collaborators
Medical College of Wisconsin
Layout table for investigator information
Principal Investigator: Jayshil J Patel, MD Medical College of Wisconsin


Layout table for additonal information
Responsible Party: Jayshil J. Patel, MD, Associate Professor of Medicine, Medical College of Wisconsin Identifier: NCT03783091     History of Changes
Other Study ID Numbers: 32950
First Posted: December 20, 2018    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Vitamin B 12
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs